The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).
Shannon Puhalla
Research Funding - AbbVie
Jan Hendrik Beumer
Research Funding - AbbVie
Shalu Pahuja
No relevant relationships to disclose
Leonard Joseph Appleman
No relevant relationships to disclose
Hussein Abdul-Hassan Tawbi
No relevant relationships to disclose
Ronald G. Stoller
No relevant relationships to disclose
James J. Lee
No relevant relationships to disclose
Yan Lin
No relevant relationships to disclose
Brian Kiesel
No relevant relationships to disclose
Jing Yu
No relevant relationships to disclose
Antoinette R. Tan
Research Funding - AbbVie
Chandra Prakash Belani
No relevant relationships to disclose
Helen K. Chew
No relevant relationships to disclose
Agustin A. Garcia
No relevant relationships to disclose
Robert Morgan
No relevant relationships to disclose
Vincent L. Giranda
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Stacie Peacock Shepherd
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie (B)
Alice P. Chen
No relevant relationships to disclose
Edward Chu
No relevant relationships to disclose